Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: GlaxoSmithKline
Current Parent Company: GSK plc
Parent at the Time of the Penalty Announcement:  subscribe to see this data field
Recap of Ownership Changes:  subscribe to see this data field
Penalty: $770,000,000
Year: 2010
Date: July 14, 2010
Offense Group: safety-related offenses
Primary Offense: drug or medical equipment safety violation
Secondary Offense: product safety violation
Mega-Scandal: Pharmaceutical Hazards
Violation Description: In July 2010 GlaxoSmithKline announced it was recording a charge of $2.36 billion to pay for legal expenses, including multi-district product liability litigation relating to claims that its diabetes drug Avandia created a heightened risk of heart attacks. The company did not specify in the announcement how much of the total was going for the Avandia cases, which were settled confidentially, but there were reports during this period of three large batches: $60 million ((click here) $460 million ((click here) and $250 million ((click here)).
Level of Government: federal
Action Type: private litigation
Court: Eastern District of Pennsylvania
Civil or Criminal Case: civil
Case ID: 2:07md1871
Case Name: In Re:Avandia Marketing, Sales Practices And Products Liability Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: United Kingdom
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.